Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a single-armed, multicenter, non-blinded phase 2 study to assess efficacy of
induction ipilimumab + nivolumab followed by chemoradiation to spare the bladder in
urothelial bladder cancer.